E Fund CSI Innovative Drugs ETF(516080) Falls 2.34%; Institutions: March Innovative Medicine Rebound Benefits from Normalized BD Transactions

NewTimeSpace News - As of 10:58 on April 3, 2026, the E Fund Innovative Medicine ETF (516080) fell 2.34%, with its latest price at 0.67 yuan. Looking at a longer timeframe, as of April 2, 2026, the ETF has accumulated a gain of 11.93% over the past week, ranking 1st among 7 comparable funds. (The stocks listed above are solely index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the E Fund Innovative Medicine ETF recorded an intraday turnover rate of 2.97% and a trading volume of 38.8074 million yuan. Looking at a longer timeframe, as of April 2, the ETF's average daily trading volume reached 77.4933 million yuan over the past week, ranking among the top 3 comparable funds.

Regarding fund size, the E Fund Innovative Medicine ETF's latest AUM stands at 1.329 billion yuan, hitting a new high for the past year and ranking 3rd among 7 comparable funds. (Data source: Wind)

In terms of fund shares, the E Fund Innovative Medicine ETF's latest share count reached 1.941 billion shares, hitting a new high for the past year and ranking 3rd among 7 comparable funds. (Data source: Wind)

For capital flows, the E Fund Innovative Medicine ETF has recorded continuous net inflows over the past 4 days, with a maximum single-day net inflow of 28.4562 million yuan, totaling 42.6375 million yuan attracted, representing an average daily net inflow of 10.6594 million yuan. (Data source: Wind)

Data indicates continued positioning by leveraged funds. The E Fund Innovative Medicine ETF has recorded continuous net margin purchases for 3 consecutive days, with a maximum single-day net purchase of 4.4494 million yuan, and its latest margin balance reaching 30.2337 million yuan. (Data source: Wind)

As of April 2, the E Fund Innovative Medicine ETF has gained 29.75% over the past 2 years, ranking first among comparable funds. In terms of return capability, as of April 2, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.96%, a maximum consecutive rising period of 5 months, a maximum consecutive gain of 33.43%, and an average monthly return of 5.75% during rising months. As of April 2, 2026, the E Fund Innovative Medicine ETF has outperformed its benchmark by 3.16% in annualized returns since inception.

Regarding drawdown, as of April 2, 2026, the E Fund Innovative Medicine ETF's relative benchmark drawdown this year was 0.05%, demonstrating relatively lower drawdown risk among comparable funds.

In terms of fee structure, the E Fund Innovative Medicine ETF charges a management fee of 0.15% and a custody fee of 0.05%, representing the lowest fee level among comparable funds.

For tracking accuracy, as of April 2, 2026, the E Fund Innovative Medicine ETF's tracking error over the past month was 0.012%.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by the ETF currently has a price-to-earnings ratio (PE-TTM) of only 44.38x, standing at the 7.63rd percentile over the past year, meaning the valuation is lower than 92.37% of the time during the past year, indicating a historically low level.

The E Fund Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index, which selects up to 50 most representative listed companies from among those whose main business involves innovative drug research and development as index constituents to reflect the overall performance of innovative medicine industry listed companies.

Zhongtai Securities stated that the March 2026 innovative medicine rebound was primarily driven by normalized BD transactions, continued volume growth of commercialized products optimizing financial statements, and enhanced expectations for key data readouts at AACR 2026 and ASCO 2026, further strengthening the logic of "overseas expansion shifting from follow to leadership." The Hong Kong biotech and pharmaceutical index has been sufficiently adjusted and formed technical support. Against the backdrop of AI tech stock corrections, innovative medicine has become a "safe-haven direction" within growth stocks that offers safety margins.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.